by CheckRare Staff | Feb 3, 2022
Philippe Duchateau, PhD, Chief Scientific Officer at Cellectis, describes the company’s TALEN gene editing technology and its application in hematologic cancers. TALEN is based on a class of proteins derived from transcription activator-like effectors (TALEs),...
by James Radke, PhD | Feb 2, 2022
Srdan Verstovsek, MD, PhD, Medical Oncologist and Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses the top-line results from the phase 3 MOMENTUM trial of momelotinib in myelofibrosis patients....
by Peter Ciszewski | Feb 2, 2022
Ajai Chari, MD, from the Mount Sinai School of Medicine, discusses next steps for the TRiMM-2 study, which is investigating teclistamab and talquetamab in combination with daratumumab in relapsed/refractory multiple myeloma patients. Results from this study...
by Peter Ciszewski | Jan 28, 2022
Sihoun Hahn, MD, Director of the Wilson Disease Center of Excellence at Seattle Children’s Research Institute, gives an overview of Wilson disease. As Dr. Hahn explains, Wilson disease is a genetic disorder caused by mutations on the ATP7B gene. These mutations...
by James Radke, PhD | Jan 27, 2022
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, discusses how positive data reflecting the safety and efficacy of CAR T cell therapy to treat multiple myeloma may lead to expanded use of this group of therapies. One example...
